Results 211 to 220 of about 112,336 (261)

SERUM-PSA, F/T PSA, PSAD, PSA-TZ AND PSA VELOCITY

The Journal of Urology, 1999
The clinical value of prostate-specific antigen (PSA) density in differentiating between prostate cancer and benign prostatic hyperplasia has been the subject of several studies. In this context the question has been raised about the diagnostic benefit of PSA transition-zone density (PSA-TZ density = total PSA/transition-zone volume) in the detection ...
Bob Djavan, Mesut Remzi, Christian Seitz, Michael Marberger, Alex Zlotta, Peter Hammerer   +5 more
openaire   +3 more sources

Discordances entre les dosages de PSA : comparaison PSA, PSA libre, PSA complexé

Revue Française des Laboratoires, 1999
Resume L'antigene specifique prostatique (PSA), combine au toucher rectal, represente aujourd'hui un outil performant dans la detection precoce du cancer de la prostate. Mais la variabilite des resultats en fonction des techniques de dosage en rend l'interpretation clinique delicate.
Yvonne Fulla, Catherine Vuillemard, Maya Megarbane, Luc Nonnenmacher, Bernard Debré, Sophie Conquy, Thierry Flam, Nicolas Thiounn, Marc Zerbib   +8 more
openaire   +1 more source

Immuno-analytical characteristics of PSA and derived biomarkers (total PSA, free PSA, p2PSA)

Annales de Biologie Clinique, 2023
Prostate-specific antigen (PSA) is the recommended tumor marker for individual screening and follow-up of prostate cancer. This paper reviews main structural and physiological data about prostate specific antigen isoforms: total PSA, free PSA, [-2]proPSA (also named p2PSA).
Cédric, Desbène, Mathieu, Boissan, Sylvain, Loric, Pierre-Jean, Lamy, Laurence, Piéroni   +4 more
openaire   +2 more sources

ALIGN PsA: Advancing a Multidisciplinary Approach in PsA

Seminars in Cutaneous Medicine and Surgery, 2018
Psoriasis is a chronic skin condition that is associated with several comorbidities and co-manifestations that reduce patient quality of life. Psoriatic arthritis (PsA) is a form of spondyloarthritis that is associated with psoriasis and typically involves peripheral disease, axial disease, enthesitis, dactylitis, and skin and nail lesions.
Eric W, Baum, Sergio, Schwartzman
openaire   +2 more sources

Impact of race and baseline PSA on longitudinal PSA

International Journal of Cancer, 2005
AbstractThere is an increasing debate regarding the frequency of prostate‐specific antigen (PSA) testing and the current primary screening modality used to detect prostate cancer. The purpose of this study is to determine whether PSA screening intervals should be based on initial PSA.
Katharine, McGreevy, Keith, Rodgers, Stuart, Lipsitz, Nabil, Bissada, David, Hoel   +4 more
openaire   +2 more sources

Relevance of total PSA and free PSA prescriptions

Annales de biologie clinique, 2018
The total PSA testing has been frequently criticized for its effectiveness in the early detection of prostate cancer. These widely resumed in and out of the medical community have led to a decrease in prescriptions. Recommendations against the use of PSA for screening have been issued in France and in most countries.
Lamy, Pierre-Jean, Brouillet, Jean-Paul, Bermont, Laurent, Fouillet, Guy, Loric, Sylvain   +4 more
openaire   +3 more sources

Pro PSA : a “pro cancer” form of PSA?

Medical Hypotheses, 2005
Pro PSA, the precursor of PSA, is an inactive 244-amino acid protein secreted by prostatic cells. Pro PSA, a distinct molecular form of free PSA in serum, includes native as well as several truncated forms. Clinical studies have recently provided evidence that pro PSA is associated with prostate cancer (PCa).
Michaël, Peyromaure, Yvonne, Fulla, Bernard, Debré, Anh Tuan, Dinh-Xuan   +3 more
openaire   +2 more sources

The PSA conundrum

Radiotherapy and Oncology, 2004
Several articles have appeared recently in Radiotherapy & Oncology [4,8,9,11,15,16] that warranted a critical reappraisal of the use of Prostate Specific Antigen (PSA) levels for determining in routine clinical practice whether or not the treatment of prostate cancer by radiotherapy was successful.
openaire   +2 more sources

PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/mL

Urology, 1999
To enhance the specificity of prostate cancer (PCa) detection and reduce unnecessary biopsies in men with prostate-specific antigen (PSA) levels of 2.5 to 4.0 ng/mL, we prospectively evaluated various PSA-based diagnostic parameters.This study included 273 consecutive men with serum PSA of 2.5 to 4.0 ng/mL referred for early PCa detection or lower ...
B, Djavan, A, Zlotta, C, Kratzik, M, Remzi, C, Seitz, C C, Schulman, M, Marberger   +6 more
openaire   +2 more sources

Total PSA, free PSA/total PSA ratio, and molecular PSA detection in prostate cancer: which is clinically effective and when?

Urology, 2000
To ascertain when the serum determination of the free prostate-specific antigen (PSA)/total PSA (fPSA/tPSA) ratio is clinically useful, and whether the identification of PSA or prostate-specific membrane antigen (PSM) mRNA in circulating cells has diagnostic advantages over the determination of their protein product.fPSA, tPSA, and the fPSA/tPSA ratio ...
BASSO, DANIELA, FOGAR, PAOLA, M. G. Piva, F. Navaglia, S. Mazza, T. Prayer Galetti, E. Castellucci, PAGANO, FRANCESCO, PLEBANI, MARIO   +8 more
openaire   +2 more sources